Canakinumab Fails to Improve COVID-19 Survival https://t.co/ngThAgfHTq JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival patients hospitalized with severe COVID-19. https://t.co/pUBmt85jAC